CYTOGEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,840 KRW | -1.76% |
|
+2.31% | -5.03% |
| Sales 2022 | 761M 553K 44.29M | Sales 2023 | 3.18B 2.32M 185M | Capitalization | 257B 187M 14.98B |
|---|---|---|---|---|---|
| Net income 2022 | -18.77B -13.65M -1.09B | Net income 2023 | -15.77B -11.46M -918M | EV / Sales 2022 | 392 x |
| Net Debt 2022 | 8.5B 6.18M 495M | Net cash position 2023 | 37.31B 27.13M 2.17B | EV / Sales 2023 | 69.1 x |
| P/E ratio 2022 |
-15.2
x | P/E ratio 2023 |
-15.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.03% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.76% | ||
| 1 week | +2.31% | ||
| Current month | -7.09% | ||
| 1 month | -12.95% | ||
| 3 months | -0.08% | ||
| 6 months | -8.29% | ||
| Current year | -5.03% |
1 week
11 820.00
13 200.00
1 month
11 820.0014 400.00
Current year
10 100.0016 640.00
1 year
10 100.0019 330.00
3 years
10 100.0024 166.67
5 years
2 266.6724 166.67
10 years
2 266.6724 166.67
| Managers | Title | Age | Since |
|---|---|---|---|
Byung-Hee Jeon
CEO | Chief Executive Officer | 65 | - |
Myung-Chul Lee
AUD | Comptroller/Controller/Auditor | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byung-Hee Jeon
CEO | Chief Executive Officer | 65 | - |
Jong-Gil Lee
BRD | Director/Board Member | 55 | - |
Myung-Shin Kim
BRD | Director/Board Member | 56 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 12,840 | -1.76% | 60,248 |
| 25/04/24 | 13,070 | +4.64% | 239,432 |
| 24/04/24 | 12,490 | +3.74% | 54,565 |
| 23/04/24 | 12,040 | -3.22% | 36,702 |
| 22/04/24 | 12,440 | -0.88% | 31,105 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.03% | 209M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M |
- Stock Market
- Equities
- A217330 Stock
